REGENXBIO Inc.
RGNX
$9.66
$0.293.10%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 405.73% | -92.82% | 43.00% | 22.88% | -4.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 405.73% | -92.82% | 43.00% | 22.88% | -4.20% |
| Cost of Revenue | -11.72% | 21.04% | 15.59% | -7.47% | 8.85% |
| Gross Profit | 217.40% | -290.90% | 0.79% | 24.70% | -16.68% |
| SG&A Expenses | 8.72% | 4.71% | 48.69% | 4.28% | 5.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -73.33% | 140.00% | -93.52% | 75.68% | 55.17% |
| Total Operating Expenses | -6.95% | 16.74% | 21.20% | -4.79% | 8.05% |
| Operating Income | 146.25% | -787.41% | -12.20% | 15.57% | -12.92% |
| Income Before Tax | 132.04% | -1,580.37% | -31.19% | -3.93% | -33.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 132.04% | -1,580.37% | -31.19% | -3.93% | -33.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 132.04% | -1,580.37% | -31.19% | -3.93% | -33.75% |
| EBIT | 146.25% | -787.41% | -12.20% | 15.57% | -12.92% |
| EBITDA | 155.61% | -594.37% | -13.56% | 16.50% | -14.21% |
| EPS Basic | 131.23% | -1,550.68% | -28.95% | -2.14% | -31.46% |
| Normalized Basic EPS | 131.23% | -1,550.68% | -28.94% | -2.15% | -31.46% |
| EPS Diluted | 131.15% | -1,552.70% | -28.95% | -2.14% | -31.78% |
| Normalized Diluted EPS | 131.11% | -1,552.64% | -28.94% | -2.15% | -31.46% |
| Average Basic Shares Outstanding | 2.60% | 2.08% | 1.73% | 1.75% | 1.74% |
| Average Diluted Shares Outstanding | 2.98% | 1.93% | 1.73% | 1.75% | 1.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |